StockData
Actuate Therapeutics, Inc. logo

Actuate Therapeutics, Inc. (ACTU) company profile

ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.29−0.01 (-3.61%)

Close on Nov 13, 2026Market cap $6.85MP/E –Yield –

About Actuate Therapeutics

Pharmaceutical Preparations, SIC 2834

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 beta (GSK-3β). The company centers its research and development on its lead small-molecule product candidate, elraglusib, which functions by blocking signaling pathways essential for cancer cell survival and tumor growth while also regulating anti-tumor immunity. Actuate develops elraglusib across two primary delivery formulations, including an intravenous injection and an oral tablet. Its investigational treatments aim to address adult and pediatric patient populations facing complex oncological conditions such as metastatic pancreatic ductal adenocarcinoma, pediatric refractory solid tumors including Ewing sarcoma and neuroblastoma, metastatic melanoma, and colorectal cancer.

The company operates as a clinical-stage organization with clinical trials evaluating treatments in hundreds of patients. Actuate maintains principal executive offices in Fort Worth, Texas.

Summary of the business section of Actuate Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Actuate Therapeutics, Inc.
Headquarters
Fort Worth, TX
Address
1751 River Run, Suite 400 76107
Phone
(847) 986-4190
Employees
12, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Crowe LLP, Costa Mesa, California

Stock & identifiers

Ticker
ACTU
Exchange
Nasdaq
IPO date
Aug 13, 2024
Shares outstanding
24M, Aug 13, 2026
Public float
$42.10M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1652935
CUSIP
005083100
ISIN
US0050831009
FIGI
BBG00NK7LK03
Share class FIGI
BBG00NK7LK12
EIN
47-3044785

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Daniel M. SchmittPresident, CEO and Director1,073,300
Andrew Paul MazarChief Operating Officer127,250
Paul J. LytleChief Financial Officer–
Kairos Venture Investments, LLCDirector–
Kairos Venture Partners II, L.P.Director–
Kairos Venture Opportunities I, L.P.Director–
SPV Fund LLC KairosDirector–
Kairos-Actuate SPV, L.P.Director2,487,474
James T. DemetriadesDirector–
Todd S. ThomsonDirector2,354,344
BIOS Fund II NT, LPDirector–
BIOS Fund I, LPDirector–
BIOS Fund II, LPDirector10,257,429
BIOS Fund I QP, LPDirector–
BIOS Fund II QP, LPDirector9,147,214
BIOS Fund III, LPDirector–
BIOS Fund III QP, LPDirector–
BIOS Fund III NT, LPDirector–
Bios Clinical Opportunity Fund, LPDirector1,472,797
BIOS Actuate Co-Invest II, LPDirector–
Bios Actuate Co-Invest III, LPDirector231,377
BIOS Actuate Co-Invest I, LPDirector10,196,456
Bios 2024 Co-Invest, LPDirector125,000
Aaron G.L. FletcherDirector–
Amy L. RonnebergDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Daniel M. Schmitt
President and Chief Executive Officer
$570.00K$142.33K$1.45M$2.17M-61%
Andrew P. Mazar, Ph. D.
Chief Operating Officer
$450.00K$102.15K$867.42K$1.42M+110%
Paul Lytle
Chief Financial Officer
$435.36K$79.06K$491.94K$1.01M-47%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 13, 2024
Securities offered
2,800,000
Exchange
Nasdaq
Lock-up ends (est.)
Feb 9, 2025

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“we had 12 full-time employees plus a number of contract workers, who manage and oversee all aspects of our operations, including”

Corporate history

Events identified from SEC filings

See a number that looks wrong?